Home Ingredients EpiCor® (Postbiotic Yeast Fermentate — Cargill)
Immune SupportGut Health

EpiCor® (Postbiotic Yeast Fermentate — Cargill)

Saccharomyces cerevisiae
Evidence Level
Limited
2 Clinical Trials
7 Documented Benefits
2/5 Evidence Score

EpiCor is a postbiotic ingredient from Cargill, derived from the fermentation of Saccharomyces cerevisiae (baker's yeast) and a widely used commercial postbiotic ingredient. Originally developed and studied for immune support, with a small number of manufacturer-affiliated trials reporting reduced cold/flu-like symptoms; more recent research has examined gut health applications. A randomized double-blind placebo-controlled trial showed 500 mg/day EpiCor reduced GI discomfort and constipation symptoms in adults with mild GI dysfunction. In vitro SHIME gut model studies show EpiCor increases butyrate production, Bifidobacterium abundance, and Lactobacillus colonization, supporting prebiotic-like mechanisms. The honest framing: the bulk of the clinical evidence base is on immune outcomes, but legitimate gut-specific evidence exists at the standard 500 mg dose. Useful for both immune support and as a postbiotic for mild GI discomfort/irregularity.

Studied Dose 500 mg/day.
Active Compound Yeast fermentate from Saccharomyces cerevisiae (mix of metabolites and bioactive compounds).

Benefits

Constipation and GI discomfort reduction

A randomized double-blind placebo-controlled trial showed 500 mg/day EpiCor reduced gastrointestinal discomfort and improved bowel function in adults with mild GI dysfunction. The trial used validated GI questionnaires and demonstrated meaningful symptom improvement vs placebo. This comes from a single small placebo-controlled pilot trial (Pinheiro 2017, n=80, manufacturer-linked) — the main direct gut-health evidence for EpiCor.

Supported by Trial 1

Cold and flu symptom reduction (primary evidence base)

Two small, single-site, manufacturer-affiliated RCTs (Moyad 2008 and its 2010 companion, ~116 adults each) at 500 mg/day reported fewer cold/flu-like symptoms; the 2010 trial found reduced incidence but no significant effect on symptom severity. The immune evidence base is larger than the gut evidence base but remains limited and single-team.

Supported by Trial 1

Postbiotic mechanism — gut microbiome modulation

In vitro SHIME® gut model studies show EpiCor increases butyrate production (the short-chain fatty acid that fuels colon cells), promotes Bifidobacterium and Lactobacilli growth, and shifts gut microbiome composition. Mechanism foundation for prebiotic-like effects without containing live bacteria.

Supported by Trial 1

Gut-immune axis support

EpiCor's gut microbiome modulation appears mechanistically connected to its immune effects — fermentation in the colon produces metabolites that modulate systemic immunity. Provides comprehensive support spanning both gut and immune endpoints rather than targeting just one.

Year-round daily use postbiotic

Designed for ongoing daily use rather than acute illness intervention. Postbiotic format (no live bacteria) means heat-stable, shelf-stable, no refrigeration required, and no live bacteria — practical advantages over traditional probiotics.

Pediatric immune research

One manufacturer-funded pediatric RCT (Singh 2024, n=256) reported good tolerability and lower symptom severity, but no reduction in infection incidence. Pediatric evidence is limited to this single sponsored trial.

Supported by Trial 2

Honest evidence assessment

The gut health evidence is more limited than the immune evidence, but it does exist (a placebo-controlled RCT plus in vitro mechanism studies). The Gut Health categorization is defensible based on this evidence, though buyers expecting IBS treatment or major bowel transformation should know that EpiCor is more of a 'general digestive support postbiotic' than a targeted GI therapeutic.

Supported by Trial 1

Mechanism of action

1

Postbiotic Bioactive Compounds

EpiCor contains beneficial mix of metabolites, β-glucans, mannans, polyphenols, peptides, and other bioactive compounds produced during yeast fermentation.

2

Innate Immune Activation

Activates innate immune cells including NK cells, macrophages, and neutrophils — first-line immune defense.

3

sIgA Modulation

Increases secretory IgA in mucosal surfaces — primary antibody at respiratory and GI mucosal barriers.

4

Antioxidant and Anti-Inflammatory Activity

Yeast metabolites provide antioxidant and modest anti-inflammatory effects.

5

Gut Microbiome Modulation

Modulates gut microbiome composition and supports gut-immune communication.

Clinical trials

1
EpiCor for Cold/Flu Reduction — Multiple RCTs
PubMed

Two small, single-site, manufacturer-affiliated EpiCor 500 mg/day RCTs (Moyad 2008; 2010 companion) in adults during cold/flu season.

Healthy adults across studies.

Reduced incidence of cold/flu-like symptoms vs placebo; the 2010 companion trial found no significant effect on symptom severity. Trials were small, single-site, and manufacturer-affiliated.

2
EpiCor in Children — Recent Research
PubMed

Recently published clinical research on EpiCor in pediatric populations.

Children.

One manufacturer-funded RCT (Singh 2024, n=256) reported good tolerability and lower symptom severity, but NO reduction in infection incidence.

Side effects and drug interactions

Common Potential side effects

Generally extremely well-tolerated.
Mild GI distress (rare).
Allergic reactions to yeast possible — relevant for those with yeast/mold allergies.
Postbiotic (contains no live bacteria), unlike traditional probiotics.

Important Drug interactions

Generally minimal drug interactions.
Yeast allergy — verify if allergic to baker's/brewer's yeast.
Pregnancy — limited specific safety data; generally considered safe at moderate doses; consult.
Lactation — generally safe.
Children — limited data; one manufacturer-funded RCT reported good tolerability at age-adjusted doses.

Featured in these supplement guides

Immune Support→

More Immune Support Ingredients

Immune Support
Vitamin C
Vitamin C (L-ascorbic acid) is a water-soluble essential nutrient that humans cannot synth…
Immune Support
Vitamin A
Vitamin A is a fat-soluble nutrient essential for vision, immune defense, reproduction, an…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…
Immune Support
Probiotics (Multi-strain Blends)
Multi-strain probiotic blends are the most common form of probiotic supplements — typicall…

Explore Other Ingredients

Immune Support
Turkey Tail Mushroom
Turkey tail (Trametes versicolor) is a medicinal mushroom studied mainly for immune suppor…
Metabolic Health
Inulin
Inulin is a soluble prebiotic fiber found naturally in chicory root, agave, and many veget…
Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…

Frequently asked questions about EpiCor® (Postbiotic Yeast Fermentate — Cargill)

What is EpiCor?

EpiCor is a postbiotic ingredient from Cargill, derived from the fermentation of Saccharomyces cerevisiae (baker's yeast) and a widely used commercial postbiotic ingredient.

What is EpiCor used for?

EpiCor is researched primarily for Immune Support and Gut Health. A randomized double-blind placebo-controlled trial showed 500 mg/day EpiCor reduced gastrointestinal discomfort and improved bowel function in adults with mild GI dysfunction.

What is the recommended dosage of EpiCor?

The clinically studied dose is 500 mg/day. Always follow the product label and check with a healthcare provider for personal advice.

Is EpiCor safe, and does it have side effects?

For most healthy adults, EpiCor is well tolerated at studied doses. Reported effects can include: Generally extremely well-tolerated. Mild GI distress (rare). It may also interact with some medications. EpiCor is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does EpiCor interact with any medications?

Possible interactions include: Generally minimal drug interactions. Yeast allergy — verify if allergic to baker's/brewer's yeast. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for EpiCor?

NutraSmarts rates the evidence for EpiCor as Limited (2 out of 5). It is backed by 2 clinical trials and 5 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(5 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Moyad MA, Robinson LE, Zawada ET Jr, Kittelsrud JM, Chen DG, Reeves SG, Weaver SE. Effects of a modified yeast supplement on cold/flu symptoms. Urol Nurs. 2008;28(1):50-5..PubMedUsed to support: Brand-specific (EpiCor, 500 mg/d, 12 weeks) RCT in 116 adults: fewer and shorter cold/flu symptoms vs placebo. Cohort had recent influenza vaccination. Small single-site trial; manufacturer-affiliated authors.
  2. Moyad MA, Robinson LE, Zawada ET, Kittelsrud J, Chen DG, Reeves SG, Weaver S. Immunogenic yeast-based fermentate for cold/flu-like symptoms in nonvaccinated individuals. J Altern Complement Med. 2010;16(2):213-8. doi: 10.1089/acm.2009.0310.PubMedUsed to support: Brand-specific (EpiCor, 500 mg/d, 12 weeks) RCT in 116 non-vaccinated adults: significantly reduced incidence of cold/flu-like symptoms vs placebo (no significant effect on severity). Companion to the 2008 study; small sample; manufacturer-affiliated.
  3. Evans M, Reeves S, Robinson LE. A dried yeast fermentate prevents and reduces inflammation in two separate experimental immune models. Evid Based Complement Alternat Med. 2012;2012:973041. doi: 10.1155/2012/973041.PubMedUsed to support: Brand-specific (EpiCor dried yeast fermentate) mechanistic study: reduced acute inflammation (rat carrageenan model) and established autoimmune arthritis (mouse collagen model). Preclinical (not human) and manufacturer-funded; supports anti-inflammatory mechanism rather than a clinical outcome.
  4. Pinheiro I, Robinson L, Verhelst A, Marzorati M, Winkens B, Van den Abbeele P, Possemiers S. A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial. BMC Complement Altern Med. 2017;17(1):441. doi:10.1186/s12906-017-1948-0.PubMedUsed to support: Single small manufacturer-linked pilot RCT (n=80): 500 mg/day EpiCor improved GI discomfort/constipation-related symptoms vs placebo. The main direct gut-health evidence; a small pilot.
  5. Singh RG, Sharma P, et al. Efficacy of a yeast postbiotic on cold/flu symptoms in healthy children: A randomized-controlled trial. Pediatr Res. 2024;doi:10.1038/s41390-024-03340-y.PubMedUsed to support: Manufacturer-funded pediatric RCT (n=256): reported good tolerability and lower symptom severity, but NO reduction in infection incidence.